Live Feeds
● LIVE Updated 1h ago · 10 sources tracked

Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager

Novartis has entered a licensing and option agreement with Chinese biotech Abogen Biosciences for an mRNA-encoded T cell engager. The deal is valued at up to $7.8 billion, with Novartis paying $575 million upfront for global rights to the experimental autoimmune treatment. The therapy uses an in vivo approach to produce a CD3xCD19 T cell engager inside the body, which Abogen claims may lower the risk of dangerous cytokine release. The agreement also includes options for other potential RNA programs.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (10)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novartis signed a licensing deal with Abogen Biosciences worth up to $7.8 billion.
  • ✓ Novartis will pay Abogen $575 million upfront for global rights to the experimental autoimmune treatment.
  • ✓ The therapy is an mRNA-encoded T cell engager designed to produce a CD3xCD19 T cell engager inside the body.
  • ✓ Abogen is a clinical-stage biotechnology group based in China.
🛡️ Source Corroboration: 10 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Novartis signed a licensing agreement with Abogen for an in vivo autoimmune T-cell engager.

Live updates

  1. Novartis licenses Abogen mRNA therapy in deal worth up to $7.8 billion

    Novartis has entered a licensing and option agreement with Chinese biotech Abogen Biosciences for an mRNA-encoded T cell engager. The deal is valued at up to $7.8 billion, with Novartis paying $575 million upfront for global rights to the experimental autoimmune treatment. The therapy uses an in vivo approach to produce a CD3xCD19 T cell engager inside the body, which Abogen claims may lower the risk of dangerous cytokine release. The agreement also includes options for other potential RNA programs.

    Why it matters

    Western pharmaceutical firms are increasingly sourcing innovation from China to offset the impact of the upcoming patent cliff. This deal highlights a trend of large-scale tie-ups between global drug makers and Chinese startups.

    What is confirmed

    • Novartis signed a licensing deal with Abogen Biosciences worth up to $7.8 billion.
    • Novartis will pay Abogen $575 million upfront for global rights to the experimental autoimmune treatment.
    • The therapy is an mRNA-encoded T cell engager designed to produce a CD3xCD19 T cell engager inside the body.
    • Abogen is a clinical-stage biotechnology group based in China.

    Still unconfirmed

    • The in vivo approach could reduce the likelihood of dangerous cytokine release.

    What to watch next

    • Clinical trial results for the CD3xCD19 T cell engager
    • Novartis' decision to exercise options on additional RNA programs
    Sources used for this update (10)
    1. WSJ — Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
    2. CNBC — Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
    3. fiercebiotech.com — Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
    4. axios.com — Novartis signs $7.8 billion drug deal with Chinese startup
    5. BioSpace — Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
    6. www.cnbc.com — Novartis signs $7.8 billion Abogen biotech licensing deal - CNBC
    7. www.biospace.com — Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen - BioSpace
    8. finance.yahoo.com — Novartis signs mRNA deal for about $7.8 billion with China's ...
    9. theclinicaltimes.com — Novartis signs Abogen deal worth up to $7.8 billion
    10. www.prnewswire.com — Abogen Announces Licensing and Option Agreement with Novartis ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community